Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Philippe de Jong

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Clinical Epidemiology|June 19, 2010
Two prognostic indicators of the publication rate of clinical studies were available during ethical reviewJean Philippe de Jong, Gerben Ter Riet, Dick Ludolf Willems
Sociology of Health & Illness|February 16, 2012
Ethical review from the inside: repertoires of evaluation in Research Ethics Committee meetingsJean Philippe de Jong, Myra C B van Zwieten, Dick L Willems
Journal of Medical Ethics|August 21, 2012
Research monitoring by US medical institutions to protect human subjects: compliance or quality improvement?Jean Philippe de Jong, Myra C B van Zwieten, Dick L Willems
Nederlands Tijdschrift Voor Geneeskunde|July 13, 2010
[Preventing fainting due to needles or blood]Linde A D Busweiler, Jean Philippe de Jong, Ruud Beunderman, et al.
Nature Reviews. Drug Discovery|August 31, 2013
Appropriate evidence for adaptive marketing authorizationJean Philippe de Jong, Diederick E Grobbee, Bruno Flamion, et al.
European Journal of Clinical Pharmacology|July 25, 2015
An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in EuropeHans C Ebbers, Joris Langedijk, Jacoline C Bouvy, et al.
The Lancet. Oncology|November 3, 2009
Tumour tissue: who is in control?Martine Corrette Ploem, Valesca P Retèl, Sabine C Linn, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Clinical Epidemiology|June 19, 2010
Two prognostic indicators of the publication rate of clinical studies were available during ethical reviewJean Philippe de Jong, Gerben Ter Riet, Dick Ludolf Willems
Sociology of Health & Illness|February 16, 2012
Ethical review from the inside: repertoires of evaluation in Research Ethics Committee meetingsJean Philippe de Jong, Myra C B van Zwieten, Dick L Willems
Journal of Medical Ethics|August 21, 2012
Research monitoring by US medical institutions to protect human subjects: compliance or quality improvement?Jean Philippe de Jong, Myra C B van Zwieten, Dick L Willems
Nederlands Tijdschrift Voor Geneeskunde|July 13, 2010
[Preventing fainting due to needles or blood]Linde A D Busweiler, Jean Philippe de Jong, Ruud Beunderman, et al.
Nature Reviews. Drug Discovery|August 31, 2013
Appropriate evidence for adaptive marketing authorizationJean Philippe de Jong, Diederick E Grobbee, Bruno Flamion, et al.
European Journal of Clinical Pharmacology|July 25, 2015
An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in EuropeHans C Ebbers, Joris Langedijk, Jacoline C Bouvy, et al.
The Lancet. Oncology|November 3, 2009
Tumour tissue: who is in control?Martine Corrette Ploem, Valesca P Retèl, Sabine C Linn, et al.
Pageof 1